Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin as Add-On to Insulin in Type 2 Diabetes Mellitus
NCT01862263Phase 4Terminated
- Sponsor
- Novartis
- Start
- May 2013
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of vildagliptin in type 2 diabetes mellitus (T2DM), sponsored by Novartis. Started May 2013; status: terminated.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01862263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01862263.